Hepion Pharmaceuticals, Inc.

NasdaqCM:HEPA Lagerbericht

Marktkapitalisierung: US$4.0m

Hepion Pharmaceuticals Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

John Brancaccio

Geschäftsführender

US$81.0k

Gesamtvergütung

Prozentsatz des Geschäftsführergehaltsn/a
Amtszeit als Geschäftsführerless than a year
Eigentum des Geschäftsführers0.006%
Durchschnittliche Amtszeit des Managementskeine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder2yrs

Jüngste Management Updates

Recent updates

Hepion Pharmaceuticals (NASDAQ:HEPA) Will Have To Spend Its Cash Wisely

Aug 10
Hepion Pharmaceuticals (NASDAQ:HEPA) Will Have To Spend Its Cash Wisely

We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate

Apr 25
We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate

We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate

Oct 27
We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate

Hepion Pharma rises as company begins NASH treatment trial

Aug 31

Will Hepion Pharmaceuticals (NASDAQ:HEPA) Spend Its Cash Wisely?

Jul 04
Will Hepion Pharmaceuticals (NASDAQ:HEPA) Spend Its Cash Wisely?

Hepion Pharmaceuticals CEO Robert Foster - Dash To Beat NASH

Feb 17

Hepion Pharmaceuticals: Facing The Momentous Year 2022

Jan 21

Additional Phase IIa Data Confirms Hepion's CRV431 As A Very Promising NASH Candidate Drug

Sep 21

Companies Like Hepion Pharmaceuticals (NASDAQ:HEPA) Are In A Position To Invest In Growth

Sep 14
Companies Like Hepion Pharmaceuticals (NASDAQ:HEPA) Are In A Position To Invest In Growth

Hepion Pharmaceuticals: A Promising Early-Stage Biopharma In The NASH Race

Sep 08

Treating Chronic Liver Disease - Interview With Hepion Pharmaceuticals CEO Dr. Robert Foster (Video)

May 26

What Type Of Shareholders Make Up Hepion Pharmaceuticals, Inc.'s (NASDAQ:HEPA) Share Registry?

Feb 18
What Type Of Shareholders Make Up Hepion Pharmaceuticals, Inc.'s (NASDAQ:HEPA) Share Registry?

Hepion Pharma cleared to advance final dosing cohort in NASH trial

Dec 29

Hepion Pharma to begin CRV431 testing in COVID-19 patients

Dec 22

Dosing underway in higher dose cohort with Hepion's CRV431 in NASH study

Dec 10

Hepion Pharma prices equity offering at $1.50

Nov 25

Hepion Pharmaceuticals (HEPA) Investor Presentation - Slideshow

Oct 31

Geschäftsführer

John Brancaccio (76 yo)

less than a year

Amtszeit

US$81,000

Vergütung

Mr. John Patrick Brancaccio, C.P.A, serves as Independent Non-Executive Director at Tiziana Life Sciences plc since July 2020. He is an Independent Non-Executive Director at OKYO Pharma Limited since June...

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
John Brancaccio
Interim CEO11.5yrsUS$81.00k0.0060%
$ 242.1
Timothy M. Block
Independent Director11yrsUS$72.90k0.0060%
$ 242.1
Vlad Ratziu
Member of Scientific Advisory Board1.7yrskeine Datenkeine Daten
Rohit Loomba
Member of Scientific Advisory Board1.7yrskeine Datenkeine Daten
Stephen A. Harrison
Scientific Advisory Board Chair5.3yrskeine Datenkeine Daten
Nikolai Naoumov
Member of Scientific Advisory Board1.7yrskeine Datenkeine Daten
Philippe Gallay
Member of Scientific Advisory Board8.3yrskeine Datenkeine Daten
Michael Purcell
Independent Directorless than a yearkeine Datenkeine Daten
Yury Popov
Member of Scientific Advisory Board1.7yrskeine Datenkeine Daten
Kaouthar Lbiati
Independent Director2.4yrsUS$80.50kkeine Daten

2.0yrs

Durchschnittliche Betriebszugehörigkeit

68yo

Durchschnittliches Alter

Erfahrener Vorstand: HEPADie Vorstandsmitglieder gelten nicht als erfahren ( 2 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.